Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and Gemcitabine in Previously
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Version: 3 Date: 04 Apr 2025
Reviewer:  Anwar Ashraf Abouelnasr
Reviewer's report:
The responses are satisfactory
Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and Gemcitabine in Previously
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Version: 3 Date: 04 Apr 2025
Reviewer:  Anwar Ashraf Abouelnasr
Reviewer's report:
The responses are satisfactory
Please review this paper.
user
Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and Gemcitabine in Previously
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Version: 3 Date: 04 Apr 2025
Reviewer:  Anwar Ashraf Abouelnasr
Reviewer's report:
The responses are satisfactory
assistant